title: Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes.
abstract: METHODS
  In 38 patients with myelodysplastic syndromes (MDS) the values of serum erythropoietin were measured at diagnosis and compared with the haemoglobin level. A highly significant inverse relationship was found between these two parameters, suggesting that the physiologic mechanism of erythroid progenitor cell recruitment is preserved in MDS. Fourteen transfusion-dependent patients were treated with recombinant human erythropoietin at the dose of 150 U/Kg three times weekly for at least 2 months.
  
  
  CONCLUSIONS
  Under recombinant human erythropoietin, three patients became transfusion-independent and 5 had a transient decrease of their transfusion requirement. Two patients under prolonged treatment at the same dose of erythropoietin remain in complete remission after 12 and 15 months respectively. A direct relationship between response to erythropoietin treatment and degree of bone marrow erythroid hyperplasia, coupled to an inverse correlation between response to erythropoietin and baseline serum erythropoietin levels were noted. Based on these findings, recombinant human erythropoietin may represent an effective treatment modality for selected patients with MDS.
authors.affiliation: Divisione di Ematologia, Ospedale Maggiore San Giovanni Battista, Molinette, Torino, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Depaoli
authors.forename: A
authors.initials: A
authors.lastname: Levis
authors.forename: N
authors.initials: N
authors.lastname: Isabella
authors.forename: F
authors.initials: F
authors.lastname: Ficara
authors.forename: C
authors.initials: C
authors.lastname: Priotto
authors.forename: P
authors.initials: P
authors.lastname: Lista
authors.forename: R
authors.initials: R
authors.lastname: Foà
authors.forename: L
authors.initials: L
authors.lastname: Resegotti
mesh_terms: D000368:Aged; D001803:Blood Transfusion; D001853:Bone Marrow / Q000473:pathology*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D015672:Erythroid Precursor Cells / Q000473:pathology*; D004921:Erythropoietin / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D011994:Recombinant Proteins / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin